SCHEMBL25184

SCHEMBL25184

Cc1cc(=O)oc2cc(OS(=O)(=O)O)ccc12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.76
KDM4E B2RXH2 10/20 0.76
GAA P10253 8/20 0.76
STS P08842 2/20 0.74
CA2 P00918 1/20 0.74
HSD17B10 Q99714 6/20 0.66
HPGD P15428 5/20 0.66
GLA P06280 7/20 0.63
ALPL P05186 3/20 0.63
ALPI P09923 3/20 0.63
KMT2A Q03164 3/20 0.58
MAPT P10636 2/20 0.56
ALDH2 P05091 2/20 0.56
TP53 P04637 1/20 0.56
NPBWR1 P48145 1/20 0.56
MAOB P27338 2/20 0.56
CA12 O43570 1/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30139608 1.00 ALDH1A1 (0.76) ALDH1A1KDM4EGAASTSCA2
SCHEMBL3761326 0.99 ALDH1A1 (0.74) ALDH1A1KDM4EGAASTSCA2
SCHEMBL10850187 0.87 KDM4E (1.00) ALDH1A1KDM4EGAASTSCA2
SCHEMBL38662608 0.85 ALDH1A1 (0.76) ALDH1A1KDM4EGAASTSCA2
SCHEMBL9451464 0.85 STS (1.00) ALDH1A1KDM4EGAASTSCA2
Potassium Ion SCHEMBL380405 0.84 KDM4E (0.74) ALDH1A1KDM4EGAASTSCA2
SCHEMBL3761324 0.84 KDM4E (0.74) ALDH1A1KDM4EGAASTSCA2
SCHEMBL10850733 0.83 MAOB (0.70) ALDH1A1KDM4EGAASTSCA2
SCHEMBL1358798 0.83 KDM4E (0.72) ALDH1A1KDM4EGAASTSCA2
SCHEMBL13930283 0.82 MAOB (0.71) ALDH1A1KDM4EGAASTSCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332490-B1 Compounds and methods for treating osteoarthritis ACADEMIA SINICA (TW) 2022-05-17 US claimed
EP-3911737-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES Optimvia, LLC (US) 2021-11-24 EP claimed
CN-113646427-A Engineered arylsulfate-dependent enzymes 奥普蒂姆维亚有限公司 2021-11-12 CN claimed
US-20210231645-A1 METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2021-07-29 US claimed
WO-2021119326-A1 METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-06-17 WO claimed
WO-2021061517-A1 ASSAY OF ARYLSULFATASE A ENZYMATIC ACTIVITY IN DRIED BLOOD SPOTS BY MASS SPECTROMETRY AND FLUOROMETRY UNIVERSITY OF WASHINGTON (US) 2021-04-01 WO claimed
WO-2020218950-A1 COMBINATION FOR TREATING FUNCTIONAL DISEASES OF THE GASTROINTESTINAL TRACT ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" 2020-10-29 WO claimed
WO-2020194563-A1 AGENT FOR PREVENTING OR IMPROVING SYMPTOMS OR DISEASE CAUSED BY PHENOLS 国立大学法人東北大学 2020-10-01 WO claimed
WO-2020150350-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES OPTIMVIA, LLC (US) 2020-07-23 WO claimed
US-10605803-B2 Composition for enzyme immunoassay using immunofluorescence and uses thereof BIOMERIEUX (FR) 2020-03-31 US claimed
EP-1379662-A2 SULFATASES AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-01-14 EP claimed
US-20030148920-A1 Sulfatases and methods of use thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-08-07 US claimed
US-20030147875-A1 Sulfatases and methods of use thereof NIH-DEITR 2003-08-07 US claimed
WO-2002059327-A2 SULFATASES AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-08-01 WO claimed
WO-2002018539-A2 METHOD FOR ASSAYING THE ACTIVITY OF LYSOSOMAL ENZYMES LYSOMETRIX CORPORATION (US) 2002-03-07 WO claimed
US-6225100-B1 ENZYME FROM CLOSTRIDIUM WITH STORAGE AND REACTION STABILITY; FOR EFFICIENT SULFATION OF TYROSYLPEPTIDES SUCH AS CHOLECYSTOKININ DCV, INC. 2001-05-01 US claimed
WO-1998003636-A9 NOVEL ARYLSULFOTRANSFERASE 1998-05-22 WO claimed
WO-1998003636-A1 NOVEL ARYLSULFOTRANSFERASE BIO-TECHNICAL RESOURCES (US) 1998-01-29 WO claimed
US-5094944-A Umbelliferyl containing substrates HAYES KENNETH R (US) 1992-03-10 US claimed
WO-1990012886-A1 FLUORESCENT AQUATIC BIOASSAY AND PROCEDURE HAYES KENNETH R (US) 1990-11-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332490-B1 Compounds and methods for treating osteoarthritis SULT1E1, STS, ARSA ALDH1A1 288/4885KDM4E 1513/4885GAA 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.